The creation of treasury shares gives management a ready source of equity for future capital raises or strategic transactions. Monitor for any subsequent announcement of a financing or share issuance from these treasury shares, which would then cause dilution.
Price Chart
Executive Summary
Addex Therapeutics issued 93,000,000 new registered shares to its wholly-owned subsidiary Addex Pharma S.A., increasing issued share capital to CHF 3,116,544.96 (311,654,496 shares) while outstanding shares remain unchanged. The shares were created as treasury shares to provide future financing flexibility, with no immediate dilution to existing shareholders.
Key Facts
- 93,000,000 new registered shares at CHF 0.01 nominal value issued to wholly-owned subsidiary Addex Pharma S.A.
- Issued share capital increased to CHF 3,116,544.96 representing 311,654,496 issued shares
- Number of outstanding shares remains unchanged
- Shares issued from the company's capital band and listed on SIX Swiss Exchange
- Transaction executed to provide additional future financing flexibility
Financial Impact
No immediate financial impact; 93M treasury shares created for potential future financing, no dilution to outstanding shares
Risk Factors
- Potential future dilution if treasury shares are sold or issued to third parties
- Company had only CHF 1.6M cash as of FY2025 year-end with going concern emphasis, suggesting near-term financing need is likely
- Activist investor Tim Dyer is CEO and has filed multiple SC 13D/A filings, creating potential governance complexity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006946 |
| Exhibit: exh_991.htm | 0001171843-26-006946 |
| Document: 0001171843-26-006946-index-headers.html | 0001171843-26-006946 |
| Document: 0001171843-26-006946-index.html | 0001171843-26-006946 |
| Document: 0001171843-26-006946.txt | 0001171843-26-006946 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 6-K | $2.93 | awaiting T+60 | awaiting T+60 | $3.09 (+5.46%) |
Oct 8, 2026 24d ago | 6-K | $3.18 | awaiting T+60 | awaiting T+60 | $3.09 (−2.83%) |
Oct 2, 2026 4w ago | 6-K | $3.07 | awaiting T+60 | awaiting T+60 | $3.09 (+0.65%) |
Sep 28, 2026 4w ago | 6-K | $2.81 | awaiting T+60 | awaiting T+60 | $3.09 (−9.96%) |
Sep 25, 2026 5w ago | 6-K | $3.65 | awaiting T+60 | awaiting T+60 | $3.09 (−15.34%) |
Aug 26, 2026 9w ago | 6-K | $4.23 | awaiting T+60 | awaiting T+60 | $3.09 (+26.95%) |
Jul 8, 2026 16w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $3.09 (−47.54%) |
Jun 30, 2026 17w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $3.09 (+45.79%) |
Jun 25, 2026 18w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $3.09 (+47.98%) |
May 15, 2026 24w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $3.09 (+54.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers